Details of the Drug

General Information of Drug (ID: DMD8ZSW)

Drug Name
Rilotumumab
Indication
Disease Entry ICD 11 Status REF
Grade IV malignant glioma 2A00.0 Discontinued in Phase 2 [1]
Drug Type
Antibody
Cross-matching ID
UNII
51WEW898IJ
DrugBank ID
DB11972
TTD ID
D07AOO

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatocyte growth factor (HGF) TT4V2JM HGF_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Grade IV malignant glioma
ICD Disease Classification 2A00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Hepatocyte growth factor (HGF) DTT HGF 4.90E-01 0.13 2.73
Hepatocyte growth factor (HGF) DTT HGF 1.98E-07 1.58 2.92
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7986).
2 Clinical pipeline report, company report or official report of Amgen (2009).